GlassScriptPhysician profile
Joshua E Durham
NPI 1013194208
$2,263.52
in general payments reported to CMS, 2019-2025
27 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $69.21 · 2022: $154 · 2023: $419 · 2024: $645 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $543.72 | 2022-2025 | Signia, Ligasure |
| Laborie Medical Technologies Corp. | $352.61 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Amgen INC. | $231.23 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $161.41 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $127.82 | 2023 | |
| Pfizer INC. | $126.05 | 2019-2025 | |
| Lilly USA, LLC | $93.60 | 2019-2025 | Mounjaro, Zepbound |
| Foundation Medicine, INC. | $91.54 | 2023 | |
| Stryker Corporation | $56.99 | 2025 | Mako, Insignia, Triathlon |
| Novo Nordisk INC | $55.27 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.04 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $44.87 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $40.46 | 2025 | Recorlev |
| Janssen Pharmaceuticals, INC | $31.25 | 2019-2024 | Spravato |
| Exeltis, USA INC. | $28.07 | 2025 | Slynd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.32 | 2019 | |
| Viatris Specialty LLC | $23.65 | 2025 | Yupelri |
| Abbvie INC. | $23.61 | 2025 | |
| Dynavax Technologies Corporation | $22.07 | 2019 | |
| Inspire Medical Systems, INC. | $19.82 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $18.70 | 2025 | Symbravo |
| Corcept Therapeutics | $18.21 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $17.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2025 | Eliquis |
| Boston Scientific Corporation | $17.44 | 2025 | General - Pain Management |
| Philips North America LLC | $16.03 | 2025 | Extended Holter |
| Glaxosmithkline, LLC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.